Released Nov 3, 2026, after the close
10-Q filed Nov 3, 2026, 34 days after period end · 0001193125-26-445534
Q3 2026 · 10-Q
Revenue$19.39M$19.39M −0.9% vs Q3 2025−3.6% vs Q2 2026
Net Income$13.48M$13.48M N/M vs Q3 2025N/M vs Q2 2026
EPS Diluted$0.03$0.03 N/M vs Q3 2025N/M vs Q2 2026
Gross Profit$10,828,000+14.2%
Operating Income-$19,768,000N/M
Operating Cash Flowderived-$6,161,000N/M
Free Cash Flowderived-$6,161,000N/M
Margins · derived
Gross margin55.9%+7.4 pt vs Q3 2025
Operating margin-102.0%+66.5 pt vs Q3 2025
Net margin69.6%+247.0 pt vs Q3 2025
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $19.39M | $19.55M | $22.09M | $25.37M |
| Net Income | $13.48M | -$34.69M | -$26.94M | -$21.00M |
| EPS Diluted | $0.03 | -$0.09 | -$0.07 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR